Interim Reports
Hanmi Pharmaceutical Co. announced clinical results on HM95573, which is under development as the next-generation targeted cancer drug, at the American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO is the world's largest cancer research conference.
The company presented the interim results of phase I clinical trial on HM95573 with 35 solid cancer patients with B-RAF, N-RAS, K-RAS mutations, which is conducted at five domestic agencies, at the 52nd ASCO annual conference held at McCormick place in Chicago, the U.S., from June 3 to 7 (local time).
RAF and RAS are important proteins which deliver signals between cells, and consist of three subtyes each – A-RAF, B-RAF, C-RAF and H-RAS, K-RAS, N-RAS. When the mutation happens in the proteins, it causes the formation of tumors. In particular, the mutation of B-RAF, K-RAS and N-RAS can cause various types of cancer.
HM95573 is considered the next-generation RAF inhibitor that shows the high selectivity toward B-RAF mutant and C-RAF kinases, which deliver signals of mutant RAS proteins, minimizing side effects and resistance.
According to the interim results of the phase I clinical trial, the group which was given 200 mg of HM95573 once a day saw the decrease in tumor sizes. In particular, melanoma patients with N-RAS mutated tumors, in which there is no proven therapeutic agent up to now, showed more than 30 percent reduction in the size of tumor. More than 40 percent of patients continued the treatment for over three months without any cancer progression.